A Double-Blind, Randomized Control Trial Comparing Botulinum Toxin Type A (Botox) and Placebo in the Treatment of Idiopathic Clubfoot

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
University of British Columbia
ClinicalTrials.gov Identifier:
NCT00152347
First received: September 7, 2005
Last updated: April 3, 2014
Last verified: April 2014

September 7, 2005
April 3, 2014
September 2005
December 2012   (final data collection date for primary outcome measure)
Primary Outcome: Response to study treatment (as indicated by ankle dorsiflexion with knee in flexion of 15 degrees or greater) [ Time Frame: Unspecified ] [ Designated as safety issue: No ]
Primary Outcome: Response to study treatment (as indicated by ankle dorsiflexion with knee in flexion of 15 degrees or greater)
Complete list of historical versions of study NCT00152347 on ClinicalTrials.gov Archive Site
  • Patient outcomes collected at every patient visit including: [ Time Frame: Unspecified ] [ Designated as safety issue: No ]
  • 1. Ankle dorsiflexion with knee in extension [ Time Frame: Unspecified ] [ Designated as safety issue: No ]
  • 2. Plantarflexion [ Time Frame: Unspecified ] [ Designated as safety issue: No ]
  • 3. Heel bisector scores [ Time Frame: Unspecified ] [ Designated as safety issue: No ]
  • 4. Occurrence of recurrence [ Time Frame: Unspecified ] [ Designated as safety issue: No ]
  • Patient outcomes collected at every patient visit including:
  • 1. Ankle dorsiflexion with knee in extension
  • 2. Plantarflexion
  • 3. Heel bisector scores
  • 4. Occurrence of recurrence
Not Provided
Not Provided
 
A Double-Blind, Randomized Control Trial Comparing Botulinum Toxin Type A (Botox) and Placebo in the Treatment of Idiopathic Clubfoot
A Double-Blind, Randomized Control Trial Comparing Botulinum Toxin Type A (Botox) and Placebo in the Treatment of Idiopathic Clubfoot

The purpose of this study is to continue the work from the previous review study and determine the effectiveness of Botox in treating patients with idiopathic clubfoot by comparing outcomes of subjects treated with manipulation and casting plus Botox (treatment group) to those treated with manipulation and casting plus placebo (control group).

The null hypothesis is that manipulation and casting plus Botox is not an effective treatment for idiopathic clubfoot. The alternate hypothesis is that manipulation and casting plus Botox is an effective treatment for idiopathic clubfoot.

The study timeline is divided into five phases which have been defined based on experiences with the previous review and with clubfoot treatment in general. These phases are as follows: 1) study treatment (Botox injection versus placebo); 2) post-treatment manipulation and casting; 3) bracing and full-time maintenance; 4) intent-to-treat intervention for management of first-time non-responders (NR1) and first-time recurrences (Rec1) post-study treatment; and 5) rescue intervention for management of second-time non-responders (NR2) and second-time recurrences (Rec2) post intent-to-treat intervention.

We will utilize a double-blind randomized control trial to assess the efficacy of Botox in the treatment of idiopathic clubfoot. Patients, parents, both participating surgeons, and members of their clinical and research teams (physiotherapist, occupational therapist, orthopaedic technologist, orthotist, research assistant) will be blinded to the study group (Botox group versus control group) each subject belongs in. The pharmacist preparing the syringes for injection will not be blinded.

Subjects will be randomly assigned to receive either Botox (Treatment group) or placebo injection (Control group). Subjects in the treatment group will receive Botox injections dosed at 10 IU/kg prepared by diluting 100 IU of Botox in 1cc of unpreserved saline. If the child has bilateral clubfoot, the contents will be divided equally for injection into each gastrocnemius. Placebo injections for the control group will contain unpreserved saline at 0.1cc/kg (such that a 4.5 kg subject will receive 0.45cc).

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Idiopathic Clubfoot (Talipes Equinovarus)
Drug: Botox
See Detailed Description
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
36
December 2015
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. children presenting with idiopathic clubfoot at BC Children's Hospital and Hospital for Sick Children
  2. children ranging in age from 1 day to 2 months old
  3. children who have reached hindfoot stall
  4. children with complete pre-study data *From protocol, hindfoot stall is defined: "following initial manipulation and casting of clubfoot, when the forefoot can be abducted beyond 60 degrees but hindfoot equinus persists, requiring need for further intervention to correct the clubfoot deformity"

Exclusion Criteria:

Both
up to 2 Months
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00152347
H05-70384
No
University of British Columbia
University of British Columbia
Not Provided
Principal Investigator: Christine Alvarez, PhD University of British Columbia
University of British Columbia
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP